Question Bank › Order-of-magnitude gap

Order-of-magnitude gap

Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business

Calls Tested
489
Answered YES
13
Hit Rate
2.7%
rare by design

Regeneron Pharmaceuticals, Inc. (REGN) — this company's answers

NO on the Q4 2022 call 2023-02-03 C
The model's full reasoning — Q4 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司规模与其已服务需求之间的“规模不匹配”——即公司目前供应、服务或参与的事物,其规模、支出、数量或人口相对于公司自身当前业务而言是巨大的,以至于即使再获得一小部分份额,也能使公司规模扩大数倍。 分析要点: 1. 公司是否已实际参与其中,有真实业务可指。 2. 管理层是否明确或实质性地描绘了这种规模对比,并将其视为重点。 在电话会议中,管理层提到了多个领域,如眼科(EYLEA、aflibercept 8mg)、Dupixent、肿瘤学(Libtayo、fianlimab、odronextamab等)、COVID抗体等。但我们需要寻找的是:管理层是否明确表示公司已处于一个巨大规模的事物中,而公司目前只占其中一小部分,且这种对比是核心。 例如,在眼科领域,EYLEA是标准疗法,但公司已是市场领导者,且aflibercept 8mg尚未获批,属于未来机会。在Dupixent方面,公司提到全球销售额近80亿美元,增长44%,但未明确说公司只占巨大市场的一小部分。在肿瘤学方面,提到Libtayo在肺癌中的机会,但也是刚获批,属于新进入。 关键点:管理层是否明确说“我们只占了很小一部分”或类似表述?在转录中,有提到“Dupixent的全球净产品销售额接近80亿美元,增长44%”,但未说这是巨大市场的一小部分。在眼科,提到“EYLEA类别份额接近约50%的注射量”,这表示公司已是主要参与者,而非小份额。 在肿瘤学,提到“Libtayo在非小细胞肺癌中的机会”,但未明确说公司只占一小部分。在COPD方面,提到“BOREAS研究”是未来数据,属于前瞻性。 因此,没有发现管理层明确描绘“公司规模远小于其已参与的巨大活动”的对比。相反,公司似乎已是其所在领域的领先者。所以答案应为NO。

← Back to the full REGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe a MISMATCH OF SCALE between the company and the demand it is already serving — that is, does management convey that the company is currently supplying, serving, or participating in something whose size, spending, volume, or population is ENORMOUS RELATIVE TO THE COMPANY'S OWN CURRENT BUSINESS, such that even a modest further share of it would make the company several times bigger than it is today? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation with BOTH of the following present: (1) THE COMPANY IS ALREADY INSIDE IT, WITH REAL BUSINESS TO POINT TO. Management describes actual, present-tense participation — orders being filled, customers being served, product shipping, work being performed, activity running now — in something identifiable and much larger than the company: a large counterparty's or industry's ongoing spending, build-out, program, or platform; a population, installed base, fleet, or footprint the company is already qualified and selling into; a category of use, market, or channel where the company's offering is already being bought. Real current activity is required — not a pipeline, not a bid outstanding, not an approval pending, not a market the company hopes to enter. (2) MANAGEMENT ITSELF DRAWS THE SIZE CONTRAST, AND TREATS IT AS THE POINT. Management makes the disproportion explicit or unmistakable in substance — for example by noting how small a fraction of the available activity, spend, sites, accounts, or units it has captured so far; by comparing a single customer, contract, program, or location's potential against the whole company's current size; by describing how much larger the thing it serves is than what the company currently earns from it; or by explaining that its own results to date reflect only the earliest sliver of what it is already positioned inside. Management should treat this gap between its present size and the scale of what it already touches as a central fact about the company, not as a passing remark, and should ground it in the concrete activity described rather than in an abstract market-size figure. The essence is ONE phenomenon: a small business standing inside a very large flow of activity that is already reaching it, where the binding question is how much of that flow it captures rather than whether the flow exists. The industry, the nature of the large flow, and the form of the company's participation may vary widely. Answer NO if the company is large relative to what it describes, or is already a leading participant with no meaningful multiple ahead of it. NO if the large opportunity is only prospective — a market not yet entered, an approval or decision still pending, a product still being developed, a customer still being pursued — rather than something the company is already inside and already earning from. NO if the only "big opportunity" language is a generic total-addressable-market number, an industry growth statistic, or promotional talk about a huge market, with no reference to how little of it this company has taken. NO if management merely reports strong demand, a good quarter, a large backlog, or a healthy pipeline without conveying the disproportion between the company's size and what it is already serving. NO if the disproportion is described only as a dependency risk or concentration concern management is trying to reduce. NO if the gap exists only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
GDRX GoodRx Holdings, Inc. Q2 2022 2022-08-08 F
FLYW Flywire Corporation Q1 2022 2022-05-14 B+
IRTC iRhythm Technologies, Inc. Q1 2022 2022-05-07 C+
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
RELY Remitly Global, Inc. Q4 2021 2022-03-02 B
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+
HSTM HealthStream, Inc. Q3 2017 2017-10-24 C

How the model reasoned

HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.

More from the question bank

Fresh change already executed, benefit mostlUpside surprise with durable, still-buildingStrong facts, held-back storyRunning ahead of their own plan — and manageThe company itself is the constraintReady-to-run scale already paid for and now All questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.